AR074467A1 - Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras. - Google Patents
Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.Info
- Publication number
- AR074467A1 AR074467A1 ARP090104667A ARP090104667A AR074467A1 AR 074467 A1 AR074467 A1 AR 074467A1 AR P090104667 A ARP090104667 A AR P090104667A AR P090104667 A ARP090104667 A AR P090104667A AR 074467 A1 AR074467 A1 AR 074467A1
- Authority
- AR
- Argentina
- Prior art keywords
- prevention
- treatment
- tetrahidropiran
- pirrolidinones
- espiro
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 2
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos de esta solicitud son moduladores de los receptores H3 y, por lo tanto, son útiles como agentes farmacéuticos, especialmente en el tratamiento y/o prevención de una variedad de enfermedades moduladas por los receptores H3, incluyendo enfermedades asociadas con el sistema nervioso central. Reivindicación 1: Un compuesto de fórmula (1) donde m es 1 o 2; n es 1 o 2; p es 1 o 2; R1 es hidrógeno, alquilo C1-4, CF3, alcoxi C1-4-alquilo C1-4, y R2 es hidrógeno, halógeno, alquilo C1-4 o CF3; o su sal o su enantiómero o diastereómero.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12008708P | 2008-12-05 | 2008-12-05 | |
| FR0955909 | 2009-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074467A1 true AR074467A1 (es) | 2011-01-19 |
Family
ID=41665099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104667A AR074467A1 (es) | 2008-12-05 | 2009-12-03 | Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8217052B2 (es) |
| EP (1) | EP2373659B1 (es) |
| JP (1) | JP5410544B2 (es) |
| KR (1) | KR101682889B1 (es) |
| CN (1) | CN102239170B (es) |
| AR (1) | AR074467A1 (es) |
| AU (1) | AU2009322243B2 (es) |
| CA (1) | CA2745715C (es) |
| CO (1) | CO6390059A2 (es) |
| CR (1) | CR20110289A (es) |
| DO (1) | DOP2011000166A (es) |
| EC (1) | ECSP11011109A (es) |
| ES (1) | ES2507574T3 (es) |
| HN (1) | HN2011001487A (es) |
| IL (1) | IL213292A (es) |
| MA (1) | MA32945B1 (es) |
| MX (1) | MX2011004791A (es) |
| MY (1) | MY150789A (es) |
| NZ (1) | NZ593150A (es) |
| PA (1) | PA8852301A1 (es) |
| PE (1) | PE20110773A1 (es) |
| RU (1) | RU2519778C2 (es) |
| TN (1) | TN2011000223A1 (es) |
| TW (1) | TWI441826B (es) |
| UA (1) | UA104880C2 (es) |
| WO (1) | WO2010065798A1 (es) |
| ZA (1) | ZA201103261B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR074466A1 (es) | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. |
| EP2569296A1 (en) * | 2010-05-11 | 2013-03-20 | Sanofi | Substituted n-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
| JP5833105B2 (ja) * | 2010-05-11 | 2015-12-16 | サノフイ | 置換ｎ−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用 |
| AR083718A1 (es) | 2010-05-11 | 2013-03-20 | Sanofi Aventis | Fenil cicloalquil pirrolidina (piperidina) espirolactamas y amidas sustituidas, preparacion y uso terapeutico de las mismas |
| WO2011143162A1 (en) | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof |
| TW201206444A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
| JP5766278B2 (ja) | 2010-05-11 | 2015-08-19 | サノフイ | 置換されたｎ−アルキルおよびｎ−アシルテトラヒドロ−イソキノリン誘導体、それらの製造および治療上の使用 |
| TW201206910A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3256276A (en) * | 1961-02-17 | 1966-06-14 | Geschickter Fund Med Res | Substituted spiroimides |
| US3258276A (en) | 1964-04-06 | 1966-06-28 | Charles E Murcott | Utility chair |
| JP4563675B2 (ja) * | 2001-10-12 | 2010-10-13 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | 置換ピペリジン類、およびヒスタミンｈ３受容体関連疾患の治療のためのその使用 |
| US6889262B1 (en) | 2002-06-26 | 2005-05-03 | Advanced Micro Devices, Inc. | Direct transaction mode for peripheral devices |
| CA2504272A1 (en) * | 2002-10-23 | 2004-05-06 | Janssen Pharmaceutica, N.V. | Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators |
| US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| JP4765627B2 (ja) * | 2003-09-22 | 2011-09-07 | Ｍｓｄ株式会社 | 新規ピペリジン誘導体 |
| WO2007005503A1 (en) * | 2005-07-01 | 2007-01-11 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
| US8158791B2 (en) * | 2005-11-10 | 2012-04-17 | Msd K.K. | Aza-substituted spiro derivatives |
| US7351708B2 (en) | 2005-12-16 | 2008-04-01 | Hoffmann-La Roche Inc. | Pyrrolo [2,3-b] pyridine derivatives |
| US20080247964A1 (en) * | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
| CA2653062A1 (en) * | 2006-05-23 | 2007-11-29 | Transtech Pharma, Inc. | 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament |
| EP2049473A2 (en) | 2006-06-29 | 2009-04-22 | Janssen Pharmaceutica N.V. | Substituted benzyl amine compounds |
| US20100317679A1 (en) | 2007-09-21 | 2010-12-16 | Ligand Pharmaceuticals, Inc. | Substituted aryl-fused spirocyclic amines |
| AU2008312636B2 (en) | 2007-10-17 | 2013-03-14 | Sanofi-Aventis | Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine H3 receptor modulators |
| SI2212283T1 (sl) * | 2007-10-17 | 2011-12-30 | Sanofi Sa | Substituirani n-fenil-bipirolidin karboksamidi in njihova terapevtska uporaba |
| BRPI0818626A2 (pt) | 2007-10-17 | 2015-09-29 | Sanofi Aventis | n-fenil-bipirrolidina carboxamidas substituída e uso terapêutico da mesma |
| AR074466A1 (es) | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. |
-
2009
- 2009-12-03 AR ARP090104667A patent/AR074467A1/es unknown
- 2009-12-04 CA CA2745715A patent/CA2745715C/en not_active Expired - Fee Related
- 2009-12-04 KR KR1020117014404A patent/KR101682889B1/ko not_active Expired - Fee Related
- 2009-12-04 NZ NZ593150A patent/NZ593150A/xx not_active IP Right Cessation
- 2009-12-04 RU RU2011127382/04A patent/RU2519778C2/ru not_active IP Right Cessation
- 2009-12-04 MA MA33989A patent/MA32945B1/fr unknown
- 2009-12-04 MX MX2011004791A patent/MX2011004791A/es active IP Right Grant
- 2009-12-04 ES ES09775421.2T patent/ES2507574T3/es active Active
- 2009-12-04 EP EP09775421.2A patent/EP2373659B1/en active Active
- 2009-12-04 JP JP2011539715A patent/JP5410544B2/ja active Active
- 2009-12-04 CN CN200980148490.7A patent/CN102239170B/zh active Active
- 2009-12-04 MY MYPI20112068 patent/MY150789A/en unknown
- 2009-12-04 UA UAA201108412A patent/UA104880C2/uk unknown
- 2009-12-04 TW TW098141444A patent/TWI441826B/zh not_active IP Right Cessation
- 2009-12-04 PE PE2011001127A patent/PE20110773A1/es not_active Application Discontinuation
- 2009-12-04 PA PA20098852301A patent/PA8852301A1/es unknown
- 2009-12-04 AU AU2009322243A patent/AU2009322243B2/en not_active Ceased
- 2009-12-04 WO PCT/US2009/066666 patent/WO2010065798A1/en not_active Ceased
-
2011
- 2011-05-05 ZA ZA2011/03261A patent/ZA201103261B/en unknown
- 2011-05-06 TN TN2011000223A patent/TN2011000223A1/fr unknown
- 2011-05-27 CR CR20110289A patent/CR20110289A/es unknown
- 2011-05-31 IL IL213292A patent/IL213292A/en not_active IP Right Cessation
- 2011-06-01 DO DO2011000166A patent/DOP2011000166A/es unknown
- 2011-06-02 US US13/151,925 patent/US8217052B2/en active Active
- 2011-06-02 CO CO11068492A patent/CO6390059A2/es active IP Right Grant
- 2011-06-03 HN HN2011001487A patent/HN2011001487A/es unknown
- 2011-06-03 EC EC2011011109A patent/ECSP11011109A/es unknown
-
2012
- 2012-05-30 US US13/483,503 patent/US8383814B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074467A1 (es) | Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras. | |
| CR20170237A (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| PE20180462A1 (es) | Moduladores cot y metodos de uso de los mismos | |
| EA201590118A1 (ru) | Производные пирролидина и их применение в качестве модуляторов пути активации комплемента | |
| SA518391307B1 (ar) | مركبات ومشتقات سبيرو [ إندول -3، 2- بيروليدين h3] أون جديدة على هيئة مثبطات الدقيقة المزدوجة للفأر(1h)2 بي2-53 | |
| EA201590200A1 (ru) | Модуляторы пути активации комплемента и их применение | |
| CL2018000036A1 (es) | Derivados etinilo | |
| GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
| CR10948A (es) | Compuestos triciclicos, composiciones y procedimientos | |
| PE20201500A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| CL2009000161A1 (es) | Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos. | |
| CL2009000404A1 (es) | Compuestos derivados de piperidin-indol-sustituidos, moduladores de receptores nociceptina/orl1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades del snc, cardiovasculares, metabolicas, entre otras. | |
| AR077080A1 (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| PE20151748A1 (es) | Inhibidores de bace1 | |
| EA201171488A1 (ru) | Lxr модуляторы | |
| CO6390058A2 (es) | Piperidina espiro pirrolidinona y piperidinona sustituidas usadas como moduladores de h3 | |
| CR20190236A (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| PE20171257A1 (es) | Analogos de urea unidos sustituidos como moduladores de sirtuina | |
| AR081908A1 (es) | N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas | |
| CL2021000421A1 (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende. | |
| CL2013003646A1 (es) | Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros. | |
| UY35158A (es) | ?moduladores selectivos del receptor de andrógenos novedosos?. | |
| CL2011000865A1 (es) | Compuestos derivados de isoquinolinona; composicion farmaceutica que los comprende; y uso del compuesto para tratar enfermedades tales como psicosis, esquizofrenia, alzheimer entre otras. | |
| MX2021002260A (es) | Compuestos utiles como moduladores de la autofagia mediada por chaperonas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |